Polyethylene glycol 3350 17000 MG Powder for Oral Solution [Miralax] — RxCUI 876195
RxNorm drug concept · Semantic branded drug
RxCUI 876195
Semantic branded drug · SBD
● Current RxNorm concept 7 FDA products
23 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI876195
Official namePolyethylene glycol 3350 17000 MG Powder for Oral Solution [Miralax]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMiralax 17 GM Powder for Oral Solution
FDA products mapped7
Package NDCs mapped23
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Polyethylene Glycol 3350: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- You can generally expect a bowel movement within 1 to 3 days after taking it. It's not meant to work in an hour like some other laxatives — it works gradually. If you haven't gone...
- How long does it take for Polyethylene Glycol 3350 to work?
- You can stir it into any 4 to 8 ounces of beverage — water, juice, coffee, tea, whatever you like, cold or hot. The key is to stir it well until it's completely dissolved. Don't dr...
- Can I mix it into any drink, or does it have to be water?
🕸️ Concept Web — How Polyethylene glycol 3350 17000 MG Powder for Ora... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Polyethylene glycol 3350 17000 MG Powder for Oral Solution [Miralax]
RxCUI 876195 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Polyethylene glycol 3350
221147IN
-
Polyethylene glycol 3350
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Miralax
261575BN
-
Miralax
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Polyethylene glycol 3350 Powder for Oral Solution
1870358SCDF -
Polyethylene glycol 3350 Oral Powder Product
1870357SCDG -
Polyethylene glycol 3350 Oral Product
1162922SCDG -
Polyethylene glycol 3350 Powder for Oral Solution [Miralax]
1870385SBDF -
Miralax Oral Powder Product
1870386SBDG -
Miralax Oral Product
1180459SBDG -
Powder for Oral Solution
1540455DF -
Oral Powder Product
1294711DFG - +1 more in this family
-
Polyethylene glycol 3350 Powder for Oral Solution
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Polyethylene glycol 3350 17000 MG Powder for Oral Solution
876193SCD -
Polyethylene glycol 3350 17000 MG
1870356SCDC -
Polyethylene glycol 3350 17000 MG [Miralax]
1870384SBDC
-
Polyethylene glycol 3350 17000 MG Powder for Oral Solution
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Polyethylene glycol 3350 17000 MG Powder for Oral Solution
SCD · 876193 -
Polyethylene glycol 3350 17000 MG
SCDC · 1870356 -
Polyethylene glycol 3350 Powder for Oral Solution
SCDF · 1870358 -
Polyethylene glycol 3350 Oral Powder Product
SCDG · 1870357 -
Polyethylene glycol 3350 Oral Product
SCDG · 1162922
Brand-Name Concepts
-
Polyethylene glycol 3350 17000 MG [Miralax]
SBDC · 1870384 -
Polyethylene glycol 3350 Powder for Oral Solution [Miralax]
SBDF · 1870385 -
Miralax Oral Powder Product
SBDG · 1870386 -
Miralax Oral Product
SBDG · 1180459 -
Miralax
BN · 261575
📦 FDA Products & Package NDCs
7 products · 23 package NDCs
23 package NDCs map to RxCUI 876195 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 11523-0122-01 | 238 g in 1 BOTTLE (11523-0122-1) | MiraLAX Orange Flavor | Bayer HealthCare LLC. | 2023-09-15 |
| 11523-0122-02 | 119 g in 1 BOTTLE (11523-0122-2) | MiraLAX Orange Flavor | Bayer HealthCare LLC. | 2023-09-15 |
| 11523-4357-02 | 2 CARTON in 1 CARTON (11523-4357-2) / 20 PACKET in 1 CARTON... | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-4357-03 | 2 BOTTLE, PLASTIC in 1 PACKAGE, COMBINATION (11523-4357-3)... | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-4357-05 | 24 PACKET in 1 CARTON (11523-4357-5) / 17 g in 1 PACKET | MiraLAX | Bayer HealthCare LLC. | 2018-05-01 |
| 11523-7234-01 | 17 g in 1 PACKET (11523-7234-1) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7234-02 | 119 g in 1 BOTTLE, PLASTIC (11523-7234-2) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7234-03 | 238 g in 1 BOTTLE, PLASTIC (11523-7234-3) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7234-04 | 510 g in 1 BOTTLE, PLASTIC (11523-7234-4) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7234-06 | 17 g in 1 PACKET (11523-7234-6) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7268-03 | 10 PACKET in 1 CARTON (11523-7268-3) / 17 g in 1 PACKET | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7268-04 | 765 g in 1 BOTTLE, PLASTIC (11523-7268-4) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7268-05 | 850 g in 1 BOTTLE, PLASTIC (11523-7268-5) | MiraLAX | Bayer HealthCare LLC. | 2025-05-30 |
| 11523-7268-08 | 24 PACKET in 1 CARTON (11523-7268-8) / 17 g in 1 PACKET | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7268-09 | 20 POUCH in 1 CARTON (11523-7268-9) / 17 g in 1 POUCH | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7341-01 | 612 g in 1 BOTTLE, PLASTIC (11523-7341-1) | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 11523-7341-02 | 3 PACKET in 1 CARTON (11523-7341-2) / 17 g in 1 PACKET | MiraLAX | Bayer HealthCare LLC. | 2007-02-01 |
| 55154-5035-06 | 6 PACKET in 1 BAG (55154-5035-6) / 17 g in 1 PACKET | MiraLAX | Cardinal Health 107, LLC | 2009-02-23 |
| 76420-0489-10 | 10 PACKET in 1 CARTON (76420-489-10) / 17 g in 1 PACKET | MiraLAX | ASCLEMED USA INC. | 2025-10-14 |
| 76420-0489-20 | 20 POUCH in 1 CARTON (76420-489-20) / 17 g in 1 POUCH | MiraLAX | ASCLEMED USA INC. | 2025-10-14 |
| 76420-0489-24 | 24 PACKET in 1 CARTON (76420-489-24) / 17 g in 1 PACKET | MiraLAX | ASCLEMED USA INC. | 2025-10-14 |
| 76420-0489-77 | 765 g in 1 BOTTLE, PLASTIC (76420-489-77) | MiraLAX | ASCLEMED USA INC. | 2025-10-14 |
| 76420-0489-85 | 850 g in 1 BOTTLE, PLASTIC (76420-489-85) | MiraLAX | ASCLEMED USA INC. | 2025-10-14 |
Observed labelers:
Bayer HealthCare LLC. (17) ·
ASCLEMED USA INC. (5) ·
Cardinal Health 107, LLC (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.